The economics of counterfeit Avastin: A geospatial and statistical analysis of demographic correlates to FDA warning letters

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 7, 2015, Pages 748-756

  Cuomo, Raphael E ^a   Mackey, Tim K ^a   Stigler, Paula ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Avastin; Counterfeit medicine; Geospatial analysis; Health economics; Pharmacoepidemiology

Indexed keywords

BEVACIZUMAB; COUNTERFEIT DRUG; ANGIOGENESIS INHIBITOR;

ARTICLE; DRUG COST; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HUMAN; INCOME; MEDICALLY UNINSURED; MEDICARE; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; REIMBURSEMENT; RISK FACTOR; STATISTICAL ANALYSIS; DEMOGRAPHY; DRUG CONTROL; ECONOMICS; GEOGRAPHIC MAPPING; HEALTH INSURANCE; LEGISLATION AND JURISPRUDENCE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; UNITED STATES;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COUNTERFEIT DRUGS; DEMOGRAPHY; DRUG AND NARCOTIC CONTROL; GEOGRAPHIC MAPPING; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SOCIOECONOMIC FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84933678890     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3796     Document Type: Article

References (33)

1. Weaver CM, Whalen J. How fake cancer drugs entered U.S. doctors' offices. Wall Street J 2012; http://online.wsj.com/news/articles/SB10001424052702303879604577410430607090226 (accessed 12 August 2014).
2. Garcia-Aguirre G, Vanzinni-Zago V, Quiroz-Mercado H. Growth of Scytalidium sp. in a counterfeit bevacizumab bottle. Indian J Ophthalmol 2013; 61(9): 523-525.
3. Mackey TK, Liang BA. Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Med 2013; 11(233).
4. Kelesidis T, Kelesidis I, Rafailidis PI, et al. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 2007; 60(2): 214-236.
5. Gostin LO, Buckley GJ, Kelley PW. Stemming the global trade in falsified and substandard medicines. JAMA 2013; 309: 1693-1694.
6. Attaran A, Barry D, Basheer S, et al. How to achieve international action on falsified and substandard medicines. BMJ 2012; 345(e7381).
7. Blackstone E, Fuhr J, Pociask S. The health and economic effects of counterfeit drugs. Am Health Drug Benefits 2014; 7(4): 216-224.
8. Berenson A. A cancer drug shows promise, at a price that many can't pay. NY Times 2006; 15: 2618-2622.
9. Mackey TK, Cuomo RE, Guerra C, et al. After counterfeit Avastin-what have we learned and what can be done? Nat Rev Clin Oncol 2015; 12(5): 302-308.
10. Mackey TK, Liang BA. Oncology and the Internet: regulatory failure and reform. J Oncol Pract 2012; 8(6): 341-343.
11. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. New England J Med 2004; 351(4): 317-319.
12. Traina TA, Rugo H, Caravelli J, et al. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol 2006; 24(18S): 3050.
13. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10(2): 145-147.
14. Ross J, Schenkein D, Pietrusko R, et al. Targeted therapies for cancer, 2004. Am J Clin Pathol 2004; 122: 598-609.
15. National Cancer Institute. FDA approval for bevacizumab. 2014; http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab (accessed 15 August 2014).
16. Genentech. About Avastin: dosing. 2014; http://www.avastin-hcp.com/about-avastin/dosing (accessed 20 August 2014).
17. Bakri S, Snyder M, Pulido J, et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006; 26(5): 519-522.
18. Keteyian A. Fake Avastin tied to small Montana distributor. CBS News. 2012; http://www.cbsnews.com/news/fake-avastin-tied-to-small-montana-distributor/ (accessed 5 September 2014).
19. National Cancer Institute. Median age of cancer patients at diagnosis, 2005-2009. SEER Program. 2009; http://seer.cancer.gov/archive/csr/1975_2009_pops09/results_single/sect_01_table.11_2pgs.pdf (accessed 20 July 2014).
20. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA: A Cancer J Clin 2014; 64(1): 9-29.
21. Levinson DR. Review of Medicare Part B Avastin and Lucentis treatments for age-related macular degeneration. Office of Inspector General: US Department of Health and Human Services, 2011.
22. McCall N, Rice T, Sangl J. Consumer knowledge of Medicare and supplemental health insurance benefits. Health Serv Res 1986; 20(6): 633-657.
23. Cubanski J, Neuman T, Demico A, et al. Examining sources of supplemental insurance and prescription drug coverage among Medicare beneficiaries: findings from the Medicare current beneficiary survey 2007. Kaiser Family Foundation 2009.
24. Lorenz K, Rosenfeld K, Asch S, et al. Charity for the dying: who receives unreimbursed hospice care? J Palliat Med 2003; 6(4): 585-591.
25. NC Department of Health and Human Services. May 2012 Medicaid bulletin. 2012; http://www.ncdhhs.gov/dma/bulletin/0512bulletin.htm (accessed 5 September 2014).
26. Denavas-Walt C, Proctor BD and Lee CH. Income, poverty, and health insurance coverage in the United States: 2005. US Census Bureau: Economics and Statistics Administration, 2006.
27. Food and Drug Administration. Letters to doctors about risks of purchasing medications from foreign or unlicensed suppliers. 2012; http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/ucm299920.htm (accessed 20 July 2014).
28. U.S. Census Bureau. Maps and data. 2014; https://www.census.gov/geo/maps-data/index.html (accessed 20 July 2014).
29. CGS Medicare. Ohio Part B Medicare bulletin. 2013; http://www.cgsmedicare.com/partb/pubs/mb_J15/2013/05_2013/PDFs/OH_2013_05.pdf (accessed 12 September 2014).
30. Lichtenfeld JL. American Cancer Society. Avastin in breast cancer: the FDA's dilemma. 2008; http://www.cancer.org/aboutus/drlensblog/post/2008/02/25/avastin-in-breast-cancer-the-fdas-dilemma.aspx (accessed 11 September 2014).
31. Finkelstein JB. Balancing patient assistance programs and physician reimbursement. Community Oncol 2006; 3(12): 767-768.
32. Burney I, Paradise J. Trends in Medicare physician participation and assignment. Health Aff 1987; 6(2): 107-120.
33. Anthem Blue Cross. Core, essential, preferred and premier plans offered by Anthem Blue Cross. Anthem Blue Cross (California). X; http://file.anthem.com/OFF_HIX_CA_KIT7.pdf (accessed 17 September 2014).